


Oncology Drug Development


Providing Strong Support
and Innovation



Our End-to-end Solutions



Our team has **an average of 10+ years of oncology experience** and **strong relationships with KOLs in Japan and Asia**, allowing them to be on top of oncology trends. Our specialists have experiences of gene therapy, immune therapy or biologic treatment studies and geographic experience, covering a wide range: from rare cancers to population-based cancers.



Collaborations with Study Groups



Use of gene mutation database in hematologic malignancies

- Partnership with National Cancer Center Japan: **HM-SCREEN- Japan** -

- Strategic consulting for Japanese market entry based on the latest understanding of unmet needs in Japan
- Proposal of candidate clinical sites and faster patient recruitment by utilizing the HM-SCREEN-Japan database and network

Experience of Different Cancers

Our broad experiences include Phase I - Phase III, basket studies, umbrella studies, and more.

Solid Tumor

- All solid cancers (all comers)
- Small cell lung cancer
- Stomach cancer
- Pancreatic cancer
- Prostate cancer
- Biliary tract cancer
- Mesothelioma
- Glioma
- Non-small cell lung cancer
- Gastrointestinal stromal tumor
- Hepatocellular carcinoma
- Colon cancer
- Breast cancer
- Ovarian cancer
- Melanoma
- Cancer of Unknown Primary

Hematologic Malignancies

- Myelodysplastic syndrome
- Chronic Myeloid Leukemia
- Multiple myeloma
- Mature B-cell Lymphoma
- Ph-positive subtype of acute lymphatic leukemia
- Primary Myelofibrosis
- Acute Myeloid Leukemia
- Mature T-cell Lymphoma
- Hodgkin's Lymphoma





Contact Us

CMIC Oncology Council

E-mail : GOnco_council@cmic.co.jp

CMIC Group website
Oncology Drug Development



<https://en.cmicgroup.com/solutions/tailored-solutions/oncology/>